« Go Back


Preparing for Pandemics

Paid Post by Gates Foundation from the New York Times

During the 1918 Spanish flu pandemic, as many as 100 million people died — up to 5 percent of the world’s population. If a similar outbreak were to happen today, the death toll could reach 360 million, despite the availability of vaccines as well as modern antiviral and antibacterial drugs. The economic impact would also be devastating, resulting in a $3 trillion economic loss, or nearly 5 percent of global GDP.

Read more

Vaccine Vision

A broad family of room temperature stable vaccines self administered via a painless patch...

read more
Featured Article
Featured Team Member

John H. Brown
President

John graduated with High Honors from Princeton in 1968 and received a Harvard MBA in 1970. He was Co-Head of Hamblet and Hayes from 1971 to 1980, when H&H was sold to CIBA-Geigy. During the next seventeen years John was with CIBA-Geigy (now renamed to Novartis), rising to become a Senior Vice President. During that period, he held many different positions including head of various points of Finance, Strategy, Business Development, Licensing, Policy, State and Federal Government Affairs, Pharmacoeconomics Research, QC/QA, Safety, Health, and Environment, and Regulatory Compliance. He also oversaw the over the counter business, CIBA-Corning Diagnostics, Biocine (a joint venture with Chiron in the Vaccine business), and the US Generics business.

After retiring from CIBA-Geigy, John was CEO of Covance Biotechnology Services, Inc., Research Triangle Park, NC, a contract manufacturer of Biopharma active ingredients (later sold to AKZO NOBEL), CEO of Integrated Biosystems, Inc., Napa, CA, a manufacturer of production equipment for Bio Pharmaceutical customers (e.g., Genentech, Amgen); (later sold to Stedim, SA, France); and President of Bausch & Lomb, London, where he oversaw Europe, Middle East & Africa. John had charge of the entire portfolio of eye care products (Surgical, Pharma, and Vision Care), representing around $2.5B in sales.

read more